Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT02131272
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kayseri, Turkey
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
- Conditions
- Interventions
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 157
- Registration Number
- NCT01966978
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2446
- Registration Number
- NCT01892319
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom
A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT01868542
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Daejeon, Korea, Republic of
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 362
- Registration Number
- NCT01835431
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1290
- Registration Number
- NCT01831765
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2287
- Registration Number
- NCT01709929
Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 131
- Registration Number
- NCT01697657
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Trelleborg, Sweden
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 37
- Registration Number
- NCT01595646
- Locations
- 🇺🇸
Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States
🇺🇸VA Puget Sound Health Care System - American Lake Division, Tacoma, Washington, United States
Efficacy and Safety of Levemir® Used as Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 631
- Registration Number
- NCT01548248
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.